Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

508 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Imaging the Met Receptor Tyrosine Kinase (Met) and Assessing Tumor Responses to a Met Tyrosine Kinase Inhibitor in Human Xenograft Mouse Models with a [99mTc] (AH-113018) or Cy 5** (AH-112543) Labeled Peptide.
Jagoda EM, Bhattacharyya S, Kalen J, Riffle L, Leeder A, Histed S, Williams M, Wong KJ, Xu B, Szajek LP, Elbuluk O, Cecchi F, Raffensperger K, Golla M, Bottaro DP, Choyke P. Jagoda EM, et al. Among authors: cecchi f. Mol Imaging. 2015;14:499-515. Mol Imaging. 2015. PMID: 26461980 Free PMC article.
Targeting the HGF/Met signalling pathway in cancer.
Cecchi F, Rabe DC, Bottaro DP. Cecchi F, et al. Eur J Cancer. 2010 May;46(7):1260-70. doi: 10.1016/j.ejca.2010.02.028. Epub 2010 Mar 19. Eur J Cancer. 2010. PMID: 20303741 Free PMC article. Review.
Targeting the HGF/Met signaling pathway in cancer therapy.
Cecchi F, Rabe DC, Bottaro DP. Cecchi F, et al. Expert Opin Ther Targets. 2012 Jun;16(6):553-72. doi: 10.1517/14728222.2012.680957. Epub 2012 Apr 25. Expert Opin Ther Targets. 2012. PMID: 22530990 Free PMC article. Review.
Immuno-PET of the hepatocyte growth factor receptor Met using the 1-armed antibody onartuzumab.
Jagoda EM, Lang L, Bhadrasetty V, Histed S, Williams M, Kramer-Marek G, Mena E, Rosenblum L, Marik J, Tinianow JN, Merchant M, Szajek L, Paik C, Cecchi F, Raffensperger K, Jose-Dizon JM, Bottaro DP, Choyke P. Jagoda EM, et al. Among authors: cecchi f. J Nucl Med. 2012 Oct;53(10):1592-600. doi: 10.2967/jnumed.111.102293. Epub 2012 Aug 23. J Nucl Med. 2012. PMID: 22917884 Free PMC article.
Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer.
Shah MA, Wainberg ZA, Catenacci DV, Hochster HS, Ford J, Kunz P, Lee FC, Kallender H, Cecchi F, Rabe DC, Keer H, Martin AM, Liu Y, Gagnon R, Bonate P, Liu L, Gilmer T, Bottaro DP. Shah MA, et al. Among authors: cecchi f. PLoS One. 2013;8(3):e54014. doi: 10.1371/journal.pone.0054014. Epub 2013 Mar 14. PLoS One. 2013. PMID: 23516391 Free PMC article. Clinical Trial.
Absolute quantitation of Met using mass spectrometry for clinical application: assay precision, stability, and correlation with MET gene amplification in FFPE tumor tissue.
Catenacci DV, Liao WL, Thyparambil S, Henderson L, Xu P, Zhao L, Rambo B, Hart J, Xiao SY, Bengali K, Uzzell J, Darfler M, Krizman DB, Cecchi F, Bottaro DP, Karrison T, Veenstra TD, Hembrough T, Burrows J. Catenacci DV, et al. Among authors: cecchi f. PLoS One. 2014 Jul 1;9(7):e100586. doi: 10.1371/journal.pone.0100586. eCollection 2014. PLoS One. 2014. PMID: 24983965 Free PMC article.
508 results